Skip to content
Disclosery

DCVC Opportunity Fund II GP, LLC

Follow

13F filer, CIK 1668343, PALO ALTO, CA

DCVC Opportunity Fund II GP, LLC reported $19,281,568 across 1 holding for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-25-111912

Period
2025-09-30
Reported value
$19.3M
Holdings
1
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RKLBexited-2,663,139-$95.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001104659-25-111912, largest first. % of portfolio is the value over $19,281,568, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RXRXRECURSION PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,951,141 shares; 2024Q4: 3,951,141 shares; 2025Q1: 3,951,141 shares; 2025Q2: 3,951,141 shares; 2025Q3: 3,951,141 shares 3,951,141$19.3M100%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RKLBROCKET LAB CORP2,663,139$95.3Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-25-111912 base2025-11-14acceptance time not in the bulk data set